Close menu

Carcinoid syndrome


Source: http://en.wikipedia.org/wiki/Carcinoid_syndrome
Updated: 2017-04-18T01:18Z
Carcinoid syndrome
Serotonin (5-HT).svg
Serotonin
Classification and external resources
Specialty{{#statements:P1995}}
ICD-10E34.0
ICD-9-CM259.2
ICD-OM8240/3-8245
DiseasesDB2040
MedlinePlus000347
eMedicinemed/271
Patient UKCarcinoid syndrome
MeSHD008303
[[[d:Lua error in Module:Wikidata at line 288: invalid escape sequence near '"^'.|edit on Wikidata]]]

Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to carcinoid tumors. The syndrome includes flushing and diarrhea, and less frequently, heart failure, emesis and bronchoconstriction.[1] It is caused by endogenous secretion of mainly serotonin and kallikrein.

Signs and symptoms

Presentation of the carcinoid syndrome.[2]

The carcinoid syndrome occurs in approximately 5% of carcinoid tumors[3] and becomes manifest when vasoactive substances from the tumors enter the systemic circulation escaping hepatic degradation. Interestingly, if the primary tumor is from the GI tract (hence releasing serotonin into the hepatic portal circulation), carcinoid syndrome generally does not occur until the disease is so advanced that it overwhelms the liver's ability to metabolize the released serotonin.[citation needed]

Pathophysiology

Carcinoid tumors produce the vasoactive substance, serotonin. It is commonly, but incorrectly, thought that serotonin is the cause of the flushing. The flushing results from secretion of kallikrein, the enzyme that catalyzes the conversion of kininogen to lysyl-bradykinin. The latter is further converted to bradykinin, one of the most powerful vasodilators known. Other components of the carcinoid syndrome are diarrhea (probably caused by the increased serotonin, which greatly increases peristalsis, leaving less time for fluid absorption), a pellagra-like syndrome (probably caused by diversion of large amounts of tryptophan from synthesis of the vitamin B3 niacin, which is needed for NAD production, to the synthesis of serotonin and other 5-hydroxyindoles), fibrotic lesions of the endocardium, particularly on the right side of the heart resulting in insufficiency of the tricuspid valve and, less frequently, the pulmonary valve and, uncommonly, bronchoconstriction. The pathogenesis of the cardiac lesions and the bronchoconstriction is unknown, but the former probably involves activation of serotonin 5-HT2B receptors by serotonin. When the primary tumor is in the gastrointestinal tract, as it is in the great majority of cases, the serotonin and kallikrein are inactivated in the liver; manifestations of carcinoid syndrome do not occur until there are metastases to the liver or when the cancer is accompanied by liver failure (cirrhosis). Carcinoid tumors arising in the bronchi may be associated with manifestations of carcinoid syndrome without liver metastases because their biologically active products reach the systemic circulation before passing through the liver and being metabolized.[citation needed]

In most patients, there is an increased urinary excretion of 5-HIAA (5-hydroxyindoleacetic acid), a degradation product of serotonin.

The biology of these tumors is interesting as it differs from many other tumor types. Ongoing research on the biology of these tumors may reveal new mechanisms for tumor development.[5]

Diagnosis

With a certain degree of clinical suspicion, the most useful initial test is the 24-hour urine levels of 5-HIAA (5-hydroxyindoleacetic acid), the end product of serotonin metabolism.[citation needed] Patients with carcinoid syndrome usually excrete more than 25 mg of 5-HIAA per day.

Imaging

For localization of both primary lesions and metastasis, the initial imaging method is Octreoscan, where indium-111 labelled somatostatin analogues (octreotide) are used in scintigraphy for detecting tumors expressing somatostatin receptors.[citation needed] Median detection rates with octreoscan are about 89%, in contrast to other imaging techniques such as CT scan and MRI with detection rates of about 80%. Gallium-68 labelled somatostatin analogues such as 68Ga-DOTA-Octreotate (DOTATATE), performed on a PET/CT scanner is superior to conventional Octreoscan.

Usually, on a CT scan, a spider-like/crab-like change is visible in the mesentery due to the fibrosis from the release of serotonin. 18F-FDG PET/CT, which evaluate for increased metabolism of glucose, may also aid in localizing the carcinoid lesion or evaluating for metastases. Chromogranin A and platelets serotonin are increased.[clarification needed]

Localization of tumour

Tumour localization may be extremely difficult.[citation needed] Barium swallow and follow-up examination of the intestine may occasionally show the tumor. Capsule video endoscopy has recently been used to localize the tumor.[citation needed] Often laparotomy is the definitive way to localize the tumour.[citation needed] Another form of localizing a tumor is the Octreoscan. A tracer agent of Indium 111 is injected into a vein where then the tumors absorb the radionuclide Indium 111 and become visible on the scanner. Only the tumors absorb the somatostatin agent Indium 111 making the scan highly effective.

Primary site of a carcinoid cancer of gut; secondaries are also visible on the mesentery

Treatment

For symptomatic relief of carcinoid syndrome:[citation needed]

Alternative treatment for qualifying candidates:

  • Surgical resection of tumor and chemotherapy (5-FU and doxorubicin)
  • Endovascular, chemoembolization, targeted chemotherapy directly delivered to the liver through special catheters mixed with embolic beads (particles that block blood vessels), used for patients with liver metastases.

Uncertainties

Disease progression is difficult to ascertain because the disease can metastasize anywhere in the body and can be too small to identify with any current technology. Markers of the condition such as chromogranin-A are imperfect indicators of disease progression.[8]

Prognosis

Prognosis varies from individual to individual. It ranges from a 95% 5-year survival for localized disease to an 80% 5-year survival for those with liver metastases.[citation needed] The average survival time from the start of octreotide treatment has increased to about 12 years.[citation needed]

Synonyms

  • Thorson-Bioerck syndrome
  • Argentaffinoma syndrome
  • Cassidy-Scholte syndrome
  • Flush syndrome

See also

References

  1. ^ Soga J, Yakuwa Y, Osaka M (1999). "Carcinoid syndrome: a statistical evaluation of 748 reported cases". Journal of Experimental & Clinical Cancer Research. 18 (2): 133–41. PMID 10464698. 
  2. ^ Table 15-14 in: Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN 1-4160-2973-7. [page needed]
  3. ^ Warrell; et al. (2010). Oxford Textbook of Medicine (8th ed.). Oxford University Press. ISBN 0-19-262922-0. [page needed]
  4. ^ E.Goljan, Pathology, 2nd ed Mosby Elsevier, Rapid Review series.[page needed]
  5. ^ Cunningham JL, Janson ET (2011). "The biological hallmarks of ileal carcinoids". European Journal of Clinical Investigation. 41 (12): 1353–60. PMID 21605115. doi:10.1111/j.1365-2362.2011.02537.x. 
  6. ^ "FDA Approves Xermelo for Carcinoid Syndrome Diarrhea". U.S. Food and Drug Administration. February 28, 2017. Retrieved 1 March 2017. 
  7. ^ "Xermelo (telotristat ethyl) Tablets, for Oral Use. Full Prescribing Information" (PDF). Lexicon Pharmaceuticals, Inc. 8800 Technology Forest Place. The Woodlands, TX 77381. Retrieved 1 March 2017. 
  8. ^ Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW (1998). "Chromogranin A: its clinical value as marker of neuroendocrine tumours". European Journal of Clinical Investigation. 28 (6): 431–40. PMID 9693933. doi:10.1046/j.1365-2362.1998.00305.x. 

Further reading

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.

Also On Wow

    Advertisement